Advances in the emergency management of pediatric sepsis

Current Opinion in Pediatrics

Volumn 18, Issue 3, 2006, Pages 245-253

  Melendez, Elliot ^a   Bachur, Richard ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Children; Pediatric; Sepsis; Shock

Indexed keywords

ACTIVATED PROTEIN C; ADRENALIN; ALBUMIN; AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLINDAMYCIN; CORTICOSTEROID; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; HYDROCORTISONE; HYPERTENSIVE AGENT; IMMUNOGLOBULIN; INOTROPIC AGENT; METHYLPREDNISOLONE; METRONIDAZOLE; MILRINONE; NITROPRUSSIDE SODIUM; NORADRENALIN; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; STARCH; VANCOMYCIN; VASODILATOR AGENT; VASOPRESSIN;

COLLOID; CONSENSUS; CRYSTALLOID; DATA ANALYSIS; EMERGENCY WARD; ERYTHROCYTE CONCENTRATE; FLUID RESUSCITATION; HEMODYNAMICS; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTION; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK;

ANTI-BACTERIAL AGENTS; CHILD; EMERGENCY MEDICAL SERVICES; FLUID THERAPY; HUMANS; SEPSIS; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 33744824098     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000193305.55635.ff     Document Type: Review

References (62)

1. Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695-701.
2. Carcillo JA. Pediatric septic shock and multiple organ failure. Crit Care Clin 2003; 19:413-440 (viii).
3. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2-8. A landmark paper on the definitions of sepsis in children.
4. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655.
5. Gebara BM. Values for systolic blood pressure. Pediatr Crit Care Med 2005; 6:500 (author reply - 1).
6. Ceneviva G, Paschall JA, Maffei F, Carcillo JA. Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 1998; 102:e19.
7. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.
8. Vincent JL, Gerlach H. Fluid resuscitation in severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004; 32 (11 Suppl):S451-S454.
9. Rackow EC, Falk JL, Fein IA, et al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 1983; 11:839-850.
10. Ngo NT, Cao XT, Kneen R, et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 2001; 32:204-213.
11. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. Br Med J 1998; 316:961-964.
12. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288:1499-1507.
13. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. Br Med J 1998; 317:235-240.
14. Choi PT, Yip G, Quinonez LG, Cook DJ. Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 1999; 27:200-210.
15. Alderson P, Schierhout G, Roberts I, Bunn F. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2000 (2):CD000567.
16. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247-2256.
17. Zimmerman JL. Use of blood products in sepsis: an evidence-based review. Crit Care Med 2004; 32 (11 Suppl):S542-S547.
18. Lucking SE, Williams TM, Chaten FC, et al. Dependence of oxygen consumption on oxygen delivery in children with hyperdynamic septic shock and low oxygen extraction. Crit Care Med 1990; 18:1316-1319.
19. Mink RB, Pollack MM. Effect of blood transfusion on oxygen consumption in pediatric septic shock. Crit Care Med 1990; 18:1087-1091.
20. Gilbert EM, Haupt MT, Mandanas RY, et al. The effect of fluid loading, blood transfusion, and catecholamine infusion on oxygen delivery and consumption in patients with sepsis. Am Rev Respir Dis 1986; 134:873-878.
21. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409-417.
22. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999; 27:639-660.
23. Malone DL, Dunne J, Tracy JK, et al. Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma 2003; 54:898-905 (discussion - 7).
24. Boldt J, Haisch G, Suttner S, et al. Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend) on measures of coagulation. Br J Anaesth 2002; 89:722-728.
25. Entholzner EK, Mielke LL, Calatzis AN, et al. Coagulation effects of a recently developed hydroxyethyl starch (HES 130/0.4) compared to hydroxyethyl starches with higher molecular weight. Acta Anaesthesiol Scand 2000; 44:1116-1121.
26. Langeron O, Doelberg M, Ang ET, et al. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 2001; 92:855-862.
27. Ng KF, Lam CC, Chan LC. In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial. Br J Anaesth 2002; 88:475-480.
28. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357:911-916.
29. Friedman G, Berlot G, Kahn RJ, Vincent JL. Combined measurements of blood lactate concentrations and gastric intramucosal pH in patients with severe sepsis. Crit Care Med 1995; 23:1184-1193.
30. Weil MH, Afifi AA. Experimental and clinical studies on lactate and pyruvate as indicators of the severity of acute circulatory failure (shock). Circulation 1970; 41:989-1001.
31. Vincent JL, Dufaye P, Berre J, et al. Serial lactate determinations during circulatory shock. Crit Care Med 1983; 11:449-451.
32. Nguyen HB, Rivers EP, Knoblich BP, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004; 32:1637-1642.
33. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 1995; 333:1025-1032.
34. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330:1717-1722.
35. Tuchschmidt J, Fried J, Astiz M, Rackow E. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 1992; 102:216-220.
36. Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103:1826-1831.
37. Bellomo R, Kellum JA, Wisniewski SR, Pinsky MR. Effects of norepinephrine on the renal vasculature in normal and endotoxemic dogs. Am J Respir Crit Care Med 1999; 159:1186-1192.
38. Desjars P, Pinaud M, Bugnon D, Tasseau F. Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 1989; 17:426-429.
39. Redl-Wenzl EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 1993; 19:151-154.
40. Fukuoka T, Nishimura M, Imanaka H, et al. Effects of norepinephrine on renal function in septic patients with normal and elevated serum lactate levels. Crit Care Med 1989; 17:1104-1107.
41. Roberts JD Jr, Fineman JR, Morin FC 3rd, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336:605-610.
42. Barton P, Garcia J, Kouatli A, et al. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study. Chest 1996; 109:1302-1312.
43. Keh D, Sprung CL. Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit Care Med 2004; 32 (11 Suppl):S527-S533.
44. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.
45. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23:1430-1439.
46. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995; 23:1294-1303.
47. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27:723-732.
48. Chawla K, Kupfer Y, Tessler S. Prognostic value of cortisol response in septic shock. JAMA 2000; 284:309.
49. Yildiz O, Doganay M, Aygen B, et al. Physiological-dose steroid therapy in sepsis. Crit Care 2002; 6:251-259.
50. Slotman GJ, Fisher CJ Jr, Bone RC, et al. Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1993; 21:191-195.
51. Briegel J, Kellermann W, Forst H, et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clin Invest 1994; 72:782-787.
52. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645-650.
53. Marik PE, Zaloga GP. Adrenal insufficiency in the critically ill: a new look at an old problem. Chest 2002; 122:1784-1796.
54. Pizarro CF, Troster EJ, Damiani D, Carcillo JA. Absolute and relative adrenal insufficiency in children with septic shock. Crit Care Med 2005; 33:855-859. An important paper which defined appropriate cortisol level or response to adrenocorticotrophic hormone (ACTH) stimulation in children to define relative adrenal insufficiency.
55. Shafazand S, Weinacker AB. Blood cultures in the critical care unit: improving utilization and yield. Chest 2002; 122:1727-1736.
56. Marcos MA, Jimenez de Anta MT, De la Bellacasa JP, et al. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults. Eur Respir J 2003; 21:209-214.
57. Bochud PY, Bonten M, Marchetti O, Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004; 32 (11 Suppl):S495-S512.
58. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554.
59. Marshall JCLS. Evaluation of the adequacy of source control in clinical trials in sepsis. New York: Springer-Verlag; 1995.
60. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
61. Fourrier F. Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review. Crit Care Med 2004; 32 (11 Suppl):S534-S541.
62. P. Eisenberg, Vice President, Global Product Safety. Discontinuation of study F1K-MC-EVBP, investigation of the efficacy and safety of drotrecogin alfa (activated) in pediatric severe sepsis. Eli Lilly and Company, 21 April 2005.